An overview of targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most aggressive adult leukemia, characterized by clonal differentiation arrest of progenitor or precursor hematopoietic cells. Intense preclinical and clinical research has led to regulatory approval of several targeted therapeutics, administered either as single...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 2023
|
| In: |
HemaSphere
Year: 2023, Jahrgang: 7, Heft: 6, Pages: 1-10 |
| ISSN: | 2572-9241 |
| DOI: | 10.1097/HS9.0000000000000914 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1097/HS9.0000000000000914 Verlag, kostenfrei, Volltext: https://journals.lww.com/hemasphere/fulltext/2023/06000/an_overview_of_targeted_therapies_in_acute_myeloid.11.aspx 
|
| Verfasserangaben: | Sven Turkalj, Felix A. Radtke, Paresh Vyas |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1962222802 | ||
| 003 | DE-627 | ||
| 005 | 20260223142818.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260223s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/HS9.0000000000000914 |2 doi | |
| 035 | |a (DE-627)1962222802 | ||
| 035 | |a (DE-599)KXP1962222802 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Turkalj, Sven |e VerfasserIn |0 (DE-588)1391071247 |0 (DE-627)1962221873 |4 aut | |
| 245 | 1 | 3 | |a An overview of targeted therapies in acute myeloid leukemia |c Sven Turkalj, Felix A. Radtke, Paresh Vyas |
| 264 | 1 | |c June 2023 | |
| 300 | |b 1 Illustration | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.02.2026 | ||
| 520 | |a Acute myeloid leukemia (AML) is the most aggressive adult leukemia, characterized by clonal differentiation arrest of progenitor or precursor hematopoietic cells. Intense preclinical and clinical research has led to regulatory approval of several targeted therapeutics, administered either as single agents or as combination therapies. However, the majority of patients still face a poor prognosis and disease relapse frequently occurs due to selection of therapy-resistant clones. Hence, more effective novel therapies, most likely as innovative, rational combination therapies, are urgently needed. Chromosomal aberrations, gene mutations, and epigenetic alterations drive AML pathogenesis but concurrently provide vulnerabilities to specifically target leukemic cells. Other molecules, either aberrantly active and/or overexpressed in leukemic stem cells, may also be leveraged for therapeutic benefit. This concise review of targeted therapies for AML treatment, which are either approved or are being actively investigated in clinical trials or recent preclinical studies, provides a flavor of the direction of travel, but also highlights the current challenges in AML treatment. | ||
| 700 | 1 | |a Radtke, Felix A. |e VerfasserIn |0 (DE-588)1234069288 |0 (DE-627)1758743158 |4 aut | |
| 700 | 1 | |a Vyas, Paresh |e VerfasserIn |0 (DE-588)1177825619 |0 (DE-627)1048932818 |0 (DE-576)517570688 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HemaSphere |d Hoboken : John Wiley & Sons Ltd., 2017 |g 7(2023), 6 vom: Juni, Artikel-ID e914, Seite 1-10 |h Online-Ressource |w (DE-627)1015324924 |w (DE-600)2922183-3 |w (DE-576)500571066 |x 2572-9241 |7 nnas |a An overview of targeted therapies in acute myeloid leukemia |
| 773 | 1 | 8 | |g volume:7 |g year:2023 |g number:6 |g month:06 |g elocationid:e914 |g pages:1-10 |g extent:10 |a An overview of targeted therapies in acute myeloid leukemia |
| 856 | 4 | 0 | |u https://doi.org/10.1097/HS9.0000000000000914 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://journals.lww.com/hemasphere/fulltext/2023/06000/an_overview_of_targeted_therapies_in_acute_myeloid.11.aspx |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260223 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 1234069288 |a Radtke, Felix A. |m 1234069288:Radtke, Felix A. |d 50000 |e 50000PR1234069288 |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1962222802 |e 4921460256 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1097/HS9.0000000000000914"],"eki":["1962222802"]},"name":{"displayForm":["Sven Turkalj, Felix A. Radtke, Paresh Vyas"]},"physDesc":[{"extent":"10 S.","noteIll":"1 Illustration"}],"language":["eng"],"recId":"1962222802","title":[{"title_sort":"overview of targeted therapies in acute myeloid leukemia","title":"An overview of targeted therapies in acute myeloid leukemia"}],"person":[{"display":"Turkalj, Sven","role":"aut","family":"Turkalj","given":"Sven"},{"family":"Radtke","display":"Radtke, Felix A.","role":"aut","given":"Felix A."},{"display":"Vyas, Paresh","role":"aut","family":"Vyas","given":"Paresh"}],"origin":[{"dateIssuedDisp":"June 2023","dateIssuedKey":"2023"}],"relHost":[{"title":[{"title_sort":"HemaSphere","title":"HemaSphere","subtitle":"open access journal of the European Hematology Association"}],"corporate":[{"display":"European Hematology Association","role":"isb"}],"origin":[{"dateIssuedKey":"2024","publisher":"John Wiley & Sons Ltd. ; Wolters Kluwer Health","publisherPlace":"Hoboken ; [Philadelphia, Pennsylvania]","dateIssuedDisp":"2024-"}],"id":{"eki":["1015324924"],"zdb":["2922183-3"],"issn":["2572-9241"]},"part":{"issue":"6","volume":"7","pages":"1-10","year":"2023","extent":"10","text":"7(2023), 6 vom: Juni, Artikel-ID e914, Seite 1-10"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"An overview of targeted therapies in acute myeloid leukemiaHemaSphere","recId":"1015324924","note":["Gesehen am 18.01.2024"],"pubHistory":["Volume 1, issue 1 (December 2017)-"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"note":["Gesehen am 23.02.2026"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a TURKALJSVEOVERVIEWOF2023 | ||